BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 36801507)

  • 1. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
    Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
    Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPRASP1 is a candidate anti-oncogene and correlates with immune microenvironment and immunotherapeutic efficiency in head and neck cancer.
    Zhang T; Liu G; Zhang J; Chen S; Deng Z; Xie M
    J Oral Pathol Med; 2023 Mar; 52(3):232-244. PubMed ID: 36264603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
    Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
    Front Immunol; 2022; 13():998266. PubMed ID: 36248785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
    Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
    World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
    Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
    Front Immunol; 2022; 13():994828. PubMed ID: 36405728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100P as a potential biomarker for immunosuppressive microenvironment in pancreatic cancer: a bioinformatics analysis and in vitro study.
    Hao W; Zhang Y; Dou J; Cui P; Zhu J
    BMC Cancer; 2023 Oct; 23(1):997. PubMed ID: 37853345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis.
    Chen Y; Zhang F; Zhang B; Trojanowicz B; Hämmerle M; Kleeff J; Sunami Y
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1990. PubMed ID: 38389400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
    Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
    J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
    Liu K; Li L; Han G
    Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of anoikis-based molecular heterogeneity in pancreatic cancer and pancreatic neuroendocrine tumor and its association with tumor immune microenvironment and metabolic remodeling.
    Li N; Jia X; Wang Z; Wang K; Qu Z; Chi D; Sun Z; Jiang J; Cui Y; Wang C
    Front Endocrinol (Lausanne); 2023; 14():1153909. PubMed ID: 37234801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment.
    Zheng X; Ma Y; Bai Y; Huang T; Lv X; Deng J; Wang Z; Lian W; Tong Y; Zhang X; Yue M; Zhang Y; Li L; Peng M
    Front Immunol; 2022; 13():984480. PubMed ID: 36389763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
    Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
    Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer germline antigen gene MAGEB2 promotes cell invasion and correlates with immune microenvironment and immunotherapeutic efficiency in laryngeal cancer.
    Cui J; Chen Y; Ou Y; Liu G; Wen Q; Zhu W; Liang L; Chen Z; Yang H; Wang L; Wei M
    Clin Immunol; 2022 Jul; 240():109045. PubMed ID: 35618211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine.
    Huang X; Chen Z; Xiang X; Liu Y; Long X; Li K; Qin M; Long C; Mo X; Tang W; Liu J
    EPMA J; 2022 Dec; 13(4):671-697. PubMed ID: 36505892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
    Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
    Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.